In the vascular business, the company is developing a next-generation DrugElutingStent, XIENCE Xpedition, which is expected to launch in Europe this year and in the U.S. in 2013.
Moderate growth is expected from vascular and diagnostics division (excluding to certain royalty and supply arrangement revenues and currency impact), after the company launched various products including its next-generation DrugElutingStent XIENCE Xpedition and XIENCE PRIME in different parts of the world.
Also late yesterday, Boston Scientific (BSX) said the U.S. Food and Drug Administration has approved its latest drug-eluting stent, the Promus Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
The new Abbott also sells medical devices such as artery-clearing drug-eluting Xience stent or its absorbable stent known as Absorb and diagnostic tests used in laboratories and hospitals such as its Architect platform.